Taysha Gene Therapies, Inc. (TSHA)Healthcare | Biotechnology | Dallas, United States | NasdaqGS
5.38 USD
-0.96
(-15.142%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 5.50 +0.12 (2.230%) ⇧ (July 13, 2026, 7:34 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 3:27 a.m. EDT
The investment case for Taysha Gene Therapies is currently defined by a stark divergence between optimistic analyst targets and deteriorating operational reality. While analysts project a 105% upside to a $13 price target, the company's fundamentals tell a different story: it is burning cash at a rapid rate with negative operating margins and no path to profitability visible in the near term. The balance sheet, while currently liquid, is being eroded by substantial free cash flow outflows, and insider selling by top executives adds a layer of skepticism regarding management's view of the stock's near-term prospects. Technically, the stock has staged a remarkable recovery from its lows, trading well above its 200-day moving average, which provides some short-term momentum support. However, the options market is screaming caution; the heavy concentration of put open interest suggests that retail and institutional traders are hedging against further downside rather than betting on an imminent surge. With no dividend to provide a floor and a valuation based entirely on future clinical success rather than current earnings, the risk/reward profile remains skewed toward the downside until the next major clinical milestone is secured and priced in. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.079566 |
| AutoETS | 0.079566 |
| MSTL | 0.086585 |
| AutoTheta | 0.092634 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 37% |
| H-stat | 0.60 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.175 |
| Excess Kurtosis | -1.36 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 32.344 |
| Revenue per Share | 0.022 |
| Market Cap | 1,546,002,304 |
| Forward P/E | -12.37 |
| Beta | 1.16 |
| Website | https://www.tayshagtx.com |
As of July 11, 2026, 3:27 a.m. EDT: Speculators are heavily positioned for downside protection with significant open interest in out-of-the-money puts (strikes 0.5, 2.5, 5.0) expiring in late 2026 and early 2027. Call activity is concentrated in the money (strikes 7.0, 9.0, 11.0, 12.0), suggesting a speculative bet on a recovery to previous highs rather than a conservative income play. The implied volatility skew shows elevated premiums for deep out-of-the-money puts compared to calls, indicating fear of further decline outweighs expectations of immediate explosive gains.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.4015152 |
| Address1 | 3,000 Pegasus Park Drive |
| Address2 | Suite 1430 |
| All Time High | 33.35 |
| All Time Low | 0.5 |
| Ask | 6.87 |
| Ask Size | 2 |
| Audit Risk | 7 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 4,157,210 |
| Average Daily Volume3 Month | 3,107,373 |
| Average Volume | 3,107,373 |
| Average Volume10Days | 4,157,210 |
| Beta | 1.155 |
| Bid | 4.43 |
| Bid Size | 2 |
| Board Risk | 9 |
| Book Value | 0.738 |
| City | Dallas |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 5.38 |
| Current Ratio | 14.044 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 6.29 |
| Day Low | 5.315 |
| Debt To Equity | 32.344 |
| Display Name | Taysha Gene Therapies |
| Earnings Call Timestamp End | 1,778,070,600 |
| Earnings Call Timestamp Start | 1,778,070,600 |
| Earnings Timestamp | 1,778,070,600 |
| Earnings Timestamp End | 1,778,070,600 |
| Earnings Timestamp Start | 1,778,070,600 |
| Ebitda | -131,406,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -10.182 |
| Enterprise To Revenue | 179.089 |
| Enterprise Value | 1,337,977,344 |
| Eps Current Year | -0.44 |
| Eps Forward | -0.435 |
| Eps Trailing Twelve Months | -0.38 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 6.166 |
| Fifty Day Average Change | -0.7859998 |
| Fifty Day Average Change Percent | -0.1274732 |
| Fifty Two Week Change Percent | 140.15152 |
| Fifty Two Week High | 7.3 |
| Fifty Two Week High Change | -1.9200001 |
| Fifty Two Week High Change Percent | -0.2630137 |
| Fifty Two Week Low | 2.34 |
| Fifty Two Week Low Change | 3.0400002 |
| Fifty Two Week Low Change Percent | 1.2991455 |
| Fifty Two Week Range | 2.34 - 7.3 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,600,954,200,000 |
| Float Shares | 205,945,896 |
| Forward Eps | -0.435 |
| Forward P E | -12.367816 |
| Free Cashflow | -73,448,000 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 99 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 1.0 |
| Gross Profits | 7,471,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.095690005 |
| Held Percent Institutions | 0.86222 |
| Implied Shares Outstanding | 287,361,020 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,020-09-24 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas. |
| Long Name | Taysha Gene Therapies, Inc. |
| Market | us_market |
| Market Cap | 1,546,002,304 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_665948579 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -129,876,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,821,868,866 |
| Number Of Analyst Opinions | 13 |
| Open | 6.29 |
| Operating Cashflow | -111,948,000 |
| Operating Margins | -17.743681 |
| Overall Risk | 10 |
| Payout Ratio | 0.0 |
| Phone | 214 612 0000 |
| Post Market Change | 0.119999886 |
| Post Market Change Percent | 2.2304811 |
| Post Market Price | 5.5 |
| Post Market Time | 1,783,985,665 |
| Previous Close | 6.34 |
| Price Eps Current Year | -12.227273 |
| Price Hint | 2 |
| Price To Book | 7.2899733 |
| Price To Sales Trailing12 Months | 206.93379 |
| Profit Margins | 0.0 |
| Quick Ratio | 13.761 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.23077 |
| Region | US |
| Regular Market Change | -0.96 |
| Regular Market Change Percent | -15.142 |
| Regular Market Day High | 6.29 |
| Regular Market Day Low | 5.315 |
| Regular Market Day Range | 5.315 - 6.29 |
| Regular Market Open | 6.29 |
| Regular Market Previous Close | 6.34 |
| Regular Market Price | 5.38 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 6,436,690 |
| Return On Assets | -0.3777 |
| Return On Equity | -0.97283995 |
| Revenue Per Share | 0.022 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 287,361,020 |
| Shares Percent Shares Out | 0.1441 |
| Shares Short | 41,397,350 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 36,014,790 |
| Short Name | Taysha Gene Therapies, Inc. |
| Short Percent Of Float | 0.1467 |
| Short Ratio | 10.84 |
| Source Interval | 15 |
| State | TX |
| Symbol | TSHA |
| Target High Price | 19.0 |
| Target Low Price | 10.0 |
| Target Mean Price | 13.0 |
| Target Median Price | 12.0 |
| Total Cash | 276,576,000 |
| Total Cash Per Share | 0.962 |
| Total Debt | 68,551,000 |
| Total Revenue | 7,471,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.38 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 5.12785 |
| Two Hundred Day Average Change | 0.25215006 |
| Two Hundred Day Average Change Percent | 0.049172666 |
| Type Disp | Equity |
| Volume | 6,436,690 |
| Website | https://www.tayshagtx.com |
| Zip | 75,247 |